These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15728403)

  • 1. Parkinson's disease: the first common neurological disease due to auto-intoxication?
    Williams AC; Cartwright LS; Ramsden DB
    QJM; 2005 Mar; 98(3):215-26. PubMed ID: 15728403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autotoxicity, methylation and a road to the prevention of Parkinson's disease.
    Williams AC; Ramsden DB
    J Clin Neurosci; 2005 Jan; 12(1):6-11. PubMed ID: 15639403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases.
    Williams AC; Ramsden DB
    Med Hypotheses; 2005; 65(2):353-62. PubMed ID: 15922112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further studies in xenobiotic metabolism and Parkinson's disease.
    Ramsden DB; Parsons RB; Ho SL; Xie T; Waring RH; Williams AC
    Adv Neurol; 2001; 86():105-13. PubMed ID: 11553967
    [No Abstract]   [Full Text] [Related]  

  • 5. The kinetic analysis of the N-methylation of 4-phenylpyridine by nicotinamide N-methyltransferase: Evidence for a novel mechanism of substrate inhibition.
    van Haren MJ; Thomas MG; Sartini D; Barlow DJ; Ramsden DB; Emanuelli M; Klamt F; Martin NI; Parsons RB
    Int J Biochem Cell Biol; 2018 May; 98():127-136. PubMed ID: 29549048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eight-fold increased risk for congenital heart defects in children carrying the nicotinamide N-methyltransferase polymorphism and exposed to medicines and low nicotinamide.
    van Driel LM; Smedts HP; Helbing WA; Isaacs A; Lindemans J; Uitterlinden AG; van Duijn CM; de Vries JH; Steegers EA; Steegers-Theunissen RP
    Eur Heart J; 2008 Jun; 29(11):1424-31. PubMed ID: 18441319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson's disease.
    Jia H; Li X; Gao H; Feng Z; Li X; Zhao L; Jia X; Zhang H; Liu J
    J Neurosci Res; 2008 Jul; 86(9):2083-90. PubMed ID: 18381761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Rapid and Efficient Assay for the Characterization of Substrates and Inhibitors of Nicotinamide N-Methyltransferase.
    van Haren MJ; Sastre Toraño J; Sartini D; Emanuelli M; Parsons RB; Martin NI
    Biochemistry; 2016 Sep; 55(37):5307-15. PubMed ID: 27570878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased beta-carboline 9N-methyltransferase activity in the frontal cortex in Parkinson's disease.
    Gearhart DA; Collins MA; Lee JM; Neafsey EJ
    Neurobiol Dis; 2000 Jun; 7(3):201-11. PubMed ID: 10860785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autism and Parkinson's disease.
    Woodward G
    Med Hypotheses; 2001 Feb; 56(2):246-9. PubMed ID: 11425297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noncoupled Fluorescent Assay for Direct Real-Time Monitoring of Nicotinamide N-Methyltransferase Activity.
    Neelakantan H; Vance V; Wang HL; McHardy SF; Watowich SJ
    Biochemistry; 2017 Feb; 56(6):824-832. PubMed ID: 28121423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Citrullination Inactivates Nicotinamide- N-methyltransferase.
    Nemmara VV; Tilvawala R; Salinger AJ; Miller L; Nguyen SH; Weerapana E; Thompson PR
    ACS Chem Biol; 2018 Sep; 13(9):2663-2672. PubMed ID: 30044909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse liver nicotinamide N-methyltransferase pharmacogenetics: biochemical properties and variation in activity among inbred strains.
    Scheller T; Orgacka H; Szumlanski CL; Weinshilboum RM
    Pharmacogenetics; 1996 Feb; 6(1):43-53. PubMed ID: 8845860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene-environment interactions in sporadic Parkinson's disease.
    Benmoyal-Segal L; Soreq H
    J Neurochem; 2006 Jun; 97(6):1740-55. PubMed ID: 16805780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitors of nicotinamide N-methyltransferase designed to mimic the methylation reaction transition state.
    van Haren MJ; Taig R; Kuppens J; Sastre Toraño J; Moret EE; Parsons RB; Sartini D; Emanuelli M; Martin NI
    Org Biomol Chem; 2017 Aug; 15(31):6656-6667. PubMed ID: 28758655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene-environment interactions in Parkinson's disease.
    Ross CA; Smith WW
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S309-15. PubMed ID: 18267256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (R)salsolinol N-methyltransferase activity increases in parkinsonian lymphocytes.
    Naoi M; Maruyama W; Nakao N; Ibi T; Sahashi K; Benedetti MS
    Ann Neurol; 1998 Feb; 43(2):212-6. PubMed ID: 9485062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine and Parkinson's disease: a dangerous liaison?
    Martignoni E; Tassorelli C; Nappi G; Zangaglia R; Pacchetti C; Blandini F
    J Neurol Sci; 2007 Jun; 257(1-2):31-7. PubMed ID: 17336337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic Mechanism of Nicotinamide N-Methyltransferase.
    Loring HS; Thompson PR
    Biochemistry; 2018 Sep; 57(38):5524-5532. PubMed ID: 30148963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of aromatase cytochrome P450 function as a risk factor for Parkinson's disease?
    Morale MC; L'Episcopo F; Tirolo C; Giaquinta G; Caniglia S; Testa N; Arcieri P; Serra PA; Lupo G; Alberghina M; Harada N; Honda S; Panzica GC; Marchetti B
    Brain Res Rev; 2008 Mar; 57(2):431-43. PubMed ID: 18063054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.